Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.34 |
| ▸ | CACNA1S | Q13698 | 8/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CYP27A1 | Q02318 | 1/20 | 0.31 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21733848 | 0.87 | CNR1 (0.32) | HCRTR2HCRTR1CNR1CNR2POLB | |
| SCHEMBL21733646 | 0.84 | HCRTR1 (0.33) | ALDH1A1HCRTR2HCRTR1CNR1CNR2 | |
| SCHEMBL21733765 | 0.84 | HCRTR1 (0.33) | ALDH1A1HCRTR2HCRTR1CNR1CNR2 | |
| SCHEMBL21733487 | 0.82 | NR3C1 (0.34) | ALDH1A1HCRTR2HCRTR1CNR1CNR2 | |
| SCHEMBL21733854 | 0.81 | NR3C1 (0.37) | MEN1ALDH1A1KMT2AHCRTR2HCRTR1 | |
| SCHEMBL21733489 | 0.80 | TSPO (0.31) | ALDH1A1HCRTR2HCRTR1CNR1CNR2 | |
| SCHEMBL21733856 | 0.79 | CACNA1S (0.33) | MEN1ALDH1A1GAAKMT2AHCRTR2 | |
| SCHEMBL26268592 | 0.79 | ALDH1A1 (0.34) | MEN1ALDH1A1GAAKMT2AHCRTR2 | |
| SCHEMBL21733808 | 0.78 | TSPO (0.35) | MEN1ALDH1A1KMT2AHCRTR2HCRTR1 | |
| SCHEMBL21733849 | 0.74 | ALDH1A1 (0.34) | MEN1ALDH1A1GAAKMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112119075-B | Condensed ring compound | 豪夫迈·罗氏有限公司 | 2024-03-12 | — | — | CN | disclosed |
| US-11760744-B2 | Fused ring compounds | GENENTECH, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| CN-112119075-A | Fused ring compound | 豪夫迈·罗氏有限公司 | 2020-12-22 | — | — | CN | disclosed |
| WO-2020035031-A1 | FUSED RING COMPOUNDS | GENENTECH, INC. (US) | 2020-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11760744-B2 | Fused ring compounds | KRAS, NRAS, HRAS | MEN1 2354/4885ALDH1A1 3678/4885GAA 2579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.